Suggested remit: To appraise the clinical and cost effectiveness of encorafenib with cetuximab and folinic acid, fluorouracil and oxaliplatin (FOLFOX) within its marketing authorisation for treating adults with untreated BRAF V600E mutation-positive metastatic colorectal cancer.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Decision publication date:
- 04 February 2026
- Prioritisation programme:
- Medicines evaluation
- Rationale:
Criteria within the (VPAG) met as a significant licence extension.
- Process:
- STA Standard
- ID number:
- 6734
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 August 2026 - 02 September 2026 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6734 |
| 05 August 2026 | In progress. Scoping commencing |
| 04 February 2026 | Awaiting development. Status change linked to topic prioritisation decision being set to Selected |
| 04 February 2026 | Topic prioritisation |
For further information on our processes and methods, please see our CHTE processes and methods manual